All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
Amra, 2021 0.47 [0.12; 1.93]
CAN-COVID, 2020 0.67 [0.30; 1.50]
CORIMUNO-ANA-1, 2021 0.91 [0.38; 2.19]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
MARIPOSA, 2021 1.43 [0.42; 4.87]
NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
Rashad, 2021 2.86 [1.36; 6.01]
Rashad, 2021 0.35 [0.17; 0.74]
RECOVERY, 2022 0.87 [0.77; 0.98]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.59 [0.33; 1.06]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Talaschian, 2021 1.56 [0.34; 7.13]
TOCOVID, 0 0.99 [0.02; 50.02]
Veiga, 2021 2.70 [0.92; 7.92]
0.76 [0.63 ; 0.90 ] ACTT-2 (Kalil), 2020, Amra, 2021, CAN-COVID, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Declercq J (COV-AID), 2021, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, MARIPOSA, 2021, NCT04377750 (HMO-0224-20), 0, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04577534 (COVIDSTORM), 0, Rashad, 2021, Rashad, 2021, RECOVERY, 2022, Rosas (REMDACTA), 2021, Rutgers, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, STOP-COVID (Guimarães), 2021, Talaschian, 2021, TOCOVID, 0, Veiga, 2021 29 36% 14,962 moderate low death or transfer to ICUdetailed results BACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88]
0.97 [0.50 ; 1.88 ] BACC Bay Tocilizumab Trial, 2020 1 0% 242 NA not evaluable deathsdetailed results ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62]
CAN-COVID, 2020 0.67 [0.30; 1.50]
Cao, 2020 0.15 [0.01; 3.29]
CORIMUNO-ANA-1, 2021 0.97 [0.46; 2.04]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
DEVENT, 0 0.47 [0.22; 1.00]
EMPACTA, 2020 1.13 [0.54; 2.40]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
Hamed, 2021 1.83 [0.16; 21.66]
Kumar, 2021 0.06 [0.00; 1.35]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
Murugesan, 2022 1.00 [0.02; 51.41]
NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
Rashad, 2021 0.46 [0.24; 0.88]
Rashad, 2021 2.16 [1.14; 4.09]
RCT-TCZ-COVID-19, 2021 2.24 [0.20; 25.37]
RECOVERY, 2021 0.85 [0.76; 0.95]
RECOVERY, 2022 0.87 [0.77; 0.98]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
REMAP-CAP sarilumab, 2021 0.51 [0.25; 1.07]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.62 [0.36; 1.07]
sarilumab phase 2 high dose, 0 0.78 [0.34; 1.80]
sarimulab phase 2 low dose, 0 1.51 [0.69; 3.32]
SAVE-MORE, 2021 0.45 [0.20; 0.99]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Soin AS (COVINTOC), 2021 0.67 [0.29; 1.55]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Talaschian, 2021 1.25 [0.30; 5.14]
TOCOVID, 0 0.99 [0.02; 50.02]
Veiga, 2021 2.70 [0.92; 7.92]
0.78 [0.70 ; 0.87 ] ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, CAN-COVID, 2020, Cao, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Declercq J (COV-AID), 2021, DEVENT, 0, EMPACTA, 2020, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, Hamed, 2021, Kumar, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, LIVE-AIR (Temesgen), 2021, Murugesan, 2022, NCT04377750 (HMO-0224-20), 0, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04577534 (COVIDSTORM), 0, Rashad, 2021, Rashad, 2021, RCT-TCZ-COVID-19, 2021, RECOVERY, 2021, RECOVERY, 2022, REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021, Rosas (REMDACTA), 2021, Rutgers, 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, SAVE-MORE, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, STOP-COVID (Guimarães), 2021, Talaschian, 2021, TOCOVID, 0, Veiga, 2021 46 22% 23,254 moderate critical deaths (time to event analysis only)detailed results ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
Rashad, 2021 2.16 [1.14; 4.09]
Rashad, 2021 0.46 [0.24; 0.88]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.62 [0.36; 1.07]
Talaschian, 2021 1.25 [0.30; 5.14]
0.81 [0.61 ; 1.08 ] ACTT-2 (Kalil), 2020, COV-BARRIER, 2021, COVACTA (Rosas), 2020, LIVE-AIR (Temesgen), 2021, Rashad, 2021, Rashad, 2021, Rosas (REMDACTA), 2021, Rutgers, 2021, Talaschian, 2021 9 63% 4,821 moderate not evaluable clinical deteriorationdetailed results BACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09]
Cao, 2020 0.11 [0.01; 2.21]
CORIMUNO-ANA-1, 2021 0.89 [0.42; 1.92]
CORIMUNO-SARI-1 (non ICU), 2021 1.01 [0.48; 2.12]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
COV-BARRIER, 2021 1.12 [0.58; 2.16]
EMPACTA, 2020 0.55 [0.33; 0.92]
RCT-TCZ-COVID-19, 2021 1.05 [0.59; 1.86]
SAVE-MORE, 2021 0.36 [0.26; 0.50]
Soin AS (COVINTOC), 2021 0.67 [0.26; 1.77]
STOP-COVID (Guimarães), 2021 0.54 [0.27; 1.07]
0.70 [0.51 ; 0.96 ] BACC Bay Tocilizumab Trial, 2020, Cao, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, COV-BARRIER, 2021, EMPACTA, 2020, RCT-TCZ-COVID-19, 2021, SAVE-MORE, 2021, Soin AS (COVINTOC), 2021, STOP-COVID (Guimarães), 2021 11 59% 2,498 moderate low clinical improvementdetailed results ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41]
CAN-COVID, 2020 1.39 [0.76; 2.54]
Cao, 2020 1.67 [0.84; 3.33]
COV-BARRIER, 2021 1.25 [1.04; 1.50]
COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Dongsheng Wang, 2020 2.37 [0.40; 13.96]
EMPACTA, 2020 1.15 [0.90; 1.47]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
REMAP-CAP sarilumab, 2021 1.76 [1.12; 2.78]
sarilumab phase 2 high dose, 0 2.09 [1.00; 4.36]
sarimulab phase 2 low dose, 0 1.51 [0.73; 3.11]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
1.26 [1.15 ; 1.39 ] ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, CAN-COVID, 2020, Cao, 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, EMPACTA, 2020, Lescure (Sarilumab 200mg), 2021, REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 16 15% 5,639 moderate critical clinical improvement (14-day)detailed results ACTT-2 (Kalil), 2020 1.30 [1.03; 1.64]
Cao, 2020 2.00 [0.58; 6.94]
COV-BARRIER, 2021 1.28 [1.05; 1.56]
COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09]
REMAP-CAP sarilumab, 2021 1.86 [1.20; 2.87]
1.37 [1.19 ; 1.57 ] ACTT-2 (Kalil), 2020, Cao, 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, REMAP-CAP sarilumab, 2021 5 0% 3,150 low serious clinical improvement (21-day)detailed results Cao, 2020 1.50 [0.22; 10.08]
1.50 [0.22 ; 10.08 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvement (28-day)detailed results COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
1.33 [0.95 ; 1.87 ] COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 4 0% 564 moderate not evaluable clinical improvement (7-day)detailed results Cao, 2020 2.38 [0.38; 14.70]
2.38 [0.38 ; 14.70 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvement (time to event analysis only)detailed results ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
Cao, 2020 1.67 [0.84; 3.33]
EMPACTA, 2020 1.15 [0.90; 1.47]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
sarimulab phase 2 low dose, 0 0.96 [0.53; 1.73]
1.14 [1.03 ; 1.27 ] ACTT-2 (Kalil), 2020, Cao, 2020, EMPACTA, 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, sarimulab phase 2 low dose, 0 6 0% 1,828 low not evaluable death or ventilationdetailed results ACTT-2 (Kalil), 2020 0.69 [0.50; 0.95]
BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81]
CORIMUNO-ANA-1, 2021 0.97 [0.62; 1.52]
CORIMUNO-SARI-1 (non ICU), 2021 1.12 [0.56; 2.22]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
EMPACTA, 2020 0.56 [0.32; 0.97]
LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98]
NCT04310228-FAVI (Zhao), 2020 3.60 [0.13; 102.66]
RECOVERY, 2021 0.85 [0.78; 0.93]
RECOVERY, 2022 0.90 [0.81; 0.99]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
Rutgers, 2021 0.65 [0.43; 0.99]
sarilumab phase 2 high dose, 0 0.39 [0.18; 0.82]
sarimulab phase 2 low dose, 0 0.70 [0.34; 1.44]
STOP-COVID (Guimarães), 2021 0.63 [0.41; 0.97]
Veiga, 2021 1.54 [0.65; 3.63]
0.82 [0.74 ; 0.90 ] ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, EMPACTA, 2020, LIVE-AIR (Temesgen), 2021, NCT04310228-FAVI (Zhao), 2020, RECOVERY, 2021, RECOVERY, 2022, Rosas (REMDACTA), 2021, Rutgers, 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, STOP-COVID (Guimarães), 2021, Veiga, 2021 16 24% 14,828 moderate low hospital dischargedetailed results EMPACTA, 2020 1.16 [0.90; 1.49]
MARIPOSA, 2021 0.88 [0.55; 1.40]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
1.03 [0.88 ; 1.19 ] EMPACTA, 2020, MARIPOSA, 2021, Rosas (REMDACTA), 2021 3 0% 649 moderate not evaluable mechanical ventilationdetailed results ACTT-2 (Kalil), 2020 0.64 [0.44; 0.93]
COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
Hamed, 2021 3.15 [0.57; 17.48]
MARIPOSA, 2021 0.88 [0.37; 2.10]
RCT-TCZ-COVID-19, 2021 1.36 [0.39; 4.69]
RECOVERY, 2022 0.87 [0.74; 1.02]
Rutgers, 2021 0.65 [0.35; 1.24]
sarilumab phase 2 high dose, 0 0.27 [0.10; 0.71]
sarimulab phase 2 low dose, 0 0.28 [0.11; 0.73]
SAVE-MORE, 2021 0.47 [0.03; 7.48]
Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48]
Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07]
Soin AS (COVINTOC), 2021 1.05 [0.46; 2.38]
0.69 [0.53 ; 0.90 ] ACTT-2 (Kalil), 2020, COVACTA (Rosas), 2020, Hamed, 2021, MARIPOSA, 2021, RCT-TCZ-COVID-19, 2021, RECOVERY, 2022, Rutgers, 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, SAVE-MORE, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021 13 40% 10,905 moderate low radiologic improvement (14-day)detailed results Cao, 2020 5.54 [1.01; 30.50]
NCT04310228-FAVI (Zhao), 2020 0.32 [0.06; 1.63]
1.32 [0.08 ; 21.51 ] Cao, 2020, NCT04310228-FAVI (Zhao), 2020 2 82% 41 moderate not evaluable ICU admissiondetailed results COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
Hamed, 2021 3.15 [0.57; 17.48]
Rutgers, 2021 0.96 [0.55; 1.68]
Soin AS (COVINTOC), 2021 1.33 [0.67; 2.64]
0.96 [0.54 ; 1.71 ] COVACTA (Rosas), 2020, Hamed, 2021, Rutgers, 2021, Soin AS (COVINTOC), 2021 4 56% 773 moderate not evaluable off oxygenationdetailed results sarilumab phase 2 high dose, 0 1.99 [0.95; 4.15]
sarimulab phase 2 low dose, 0 1.07 [0.52; 2.21]
1.46 [0.79 ; 2.68 ] sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0 2 28% 270 serious not evaluable recoverydetailed results COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20]
Talaschian, 2021 0.64 [0.14; 2.92]
1.30 [0.64 ; 2.66 ] COV-BARRIER (critically ill), 2022, Talaschian, 2021 2 9% 137 low not evaluable related AE (TRAE)detailed results Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93]
1.26 [0.14 ; 11.07 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable serious adverse eventsdetailed results BACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53]
CAN-COVID, 2020 0.73 [0.45; 1.19]
Cao, 2020 0.11 [0.01; 2.21]
COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Dongsheng Wang, 2020 0.91 [0.02; 47.31]
Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
Soin AS (COVINTOC), 2021 0.97 [0.44; 2.13]
Talaschian, 2021 7.93 [0.37; 171.38]
Veiga, 2021 1.66 [0.60; 4.59]
0.93 [0.77 ; 1.12 ] BACC Bay Tocilizumab Trial, 2020, CAN-COVID, 2020, Cao, 2020, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021, Soin AS (COVINTOC), 2021, Talaschian, 2021, Veiga, 2021 11 0% 2,723 moderate low superinfectiondetailed results ACTT-2 (Kalil), 2020 0.50 [0.32; 0.79]
0.50 [0.32 ; 0.79 ] ACTT-2 (Kalil), 2020 1 0% 1,033 NA not evaluable adverse eventsdetailed results Cao, 2020 1.60 [0.38; 6.81]
COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Dongsheng Wang, 2020 9.64 [2.76; 33.75]
Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
NCT04310228-FAVI (Zhao), 2020 0.60 [0.05; 6.80]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71]
Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01]
Soin AS (COVINTOC), 2021 1.50 [0.78; 2.87]
Veiga, 2021 1.65 [0.81; 3.37]
1.31 [0.94 ; 1.83 ] Cao, 2020, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, NCT04310228-FAVI (Zhao), 2020, Rosas (REMDACTA), 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, Veiga, 2021 11 47% 2,034 moderate low 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-08 20:15 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290